Sagimet Biosciences is a clinical-stage company developing oral fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways linked to excess palmitate. Its lead candidate, denifanstat, is a once-daily selective FASN inhibitor in development for metabolic dysfunction–associated steatohepatitis (MASH), with related work in acne through a China partner. The approach aims at diseases driven by overactive de novo lipogenesis rather than broad metabolic suppression.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -18.2 | — |
| Q2 2025 | 0 | — | -10.4 | — |
| Q3 2025 | 0 | — | -12.9 | — |
| Q4 2025 | 0 | — | -9.6 | — |
| Q1 2026 | 0 | — | -10.7 | — |
| Q2 2026 | 0 | — | -13.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Unity Bancorp, Inc. (UNTY), Kearny Financial Corp. (KRNY), Southern First Bancshares, Inc. (SFST), CorMedix Inc. (CRMD), Climb Bio Inc (CLYM), Phathom Pharmaceuticals, Inc. (PHAT)